Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 15226 - 15250 of 15268 in total

R-348

Investigational

GO-203-2C

GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid …

CRA_9785

Experimental

KB002

KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational

FavId

FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
Investigational

2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine

Experimental

6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine

Experimental

CRA_10656

Experimental

1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE

Experimental

Dihydroquinidine barbiturate

Experimental

CRA-9334

Experimental

Doramapimod

Doramapimod is a P38 MAP kinase inhibitor.
Investigational

(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

ISIS 113715

ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.
Investigational

RG-7795

Investigational

CRA_1802

Experimental

CRA_10972

Experimental

CRA_11092

Experimental

Plinabulin

Investigational

Alamifovir

Alamifovir is an antiviral agent specific for HBV.
Investigational

VLTS-589

VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational

BTA9881

BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.
Investigational

CHGN111

CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It...
Investigational

XL418

XL418 is a novel anticancer compound.
Investigational

R1295

R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Displaying drugs 15226 - 15250 of 15268 in total